Zura Bio Limited
NASDAQ:ZURABiotechnology
+$0.07 today
- Market cap
- $92.96M
- Beta
- 0.03
- P/E (TTM)
- -5.5
- EPS (TTM)
- -$0.67
Volume 3.02M
Average 0.75M
ZURA EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Zura Bio LimitedNASDAQ: ZURA
EBITDA · Q1 FY2026 · quarter ended Mar 2026
EBITDA remains negative
Q1 FY2026 EBITDA was -$24.21M, compared with -$17.43M a year earlier. Trailing-twelve-month EBITDA was -$75.38M.
Context
- EBITDA grew in size in 2 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether EBITDA reaches the consensus estimate from 6 analysts of $0 (+100.0%) for the fiscal year ending Dec 2026, a step up from the -30.9% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$24.21M-41.1% QoQ
- Last fiscal yearDec 2025
- -$68.6M-30.9% YoY
- LTMMar 2026
- -$75.38M-21.4% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -38.9% | +100.0% | +138.9 pp |
| 1 year | -30.9% | +100.0% | +130.9 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- (68.6M) USD
- Year-over-year change
- -30.9%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (68.6M) | -30.9% |
| FY2024 | 2024-12-31 | (52.39M) | +13.5% |
| FY2023 | 2023-12-31 | (60.56M) | -121.6% |
| FY2022 | 2022-12-31 | (27.33M) | -424.7% |
| FY2021 | 2021-12-31 | 8.42M | — |
EBITDA vs competitors
How ZURA compares with its peers on the latest reported figures
- ZURA's LTM Mar 2026 EBITDA of -$75.38M is the 9th highest of the 11 companies compared; the peer median is -$63.19M.
- Its year-over-year change of -21.4% is the 10th highest of 11, against a peer median of +9.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | -$6.26M | +84.1% | — | 8.8% | |
SGMTSagimet Biosciences Inc. | LTM Mar 2026 | -$46.14M | +19.2% | — | — |
| LTM Mar 2026 | -$46.56M | +46.6% | — | 67.3% | |
| LTM Mar 2026 | -$50.77M | +11.7% | — | — | |
| LTM Mar 2026 | -$58.85M | +7.0% | — | — | |
| LTM Mar 2026 | -$67.53M | -3.7% | — | 148.9% | |
| LTM Mar 2026 | -$69.83M | -147.0% | — | — | |
| LTM Mar 2026 | -$72.53M | +7.7% | — | 257.0% | |
ZURAZura Bio Limited | LTM Mar 2026 | -$75.38M | -21.4% | — | — |
| LTM Mar 2026 | -$75.47M | +22.0% | — | 33540.9% | |
| LTM Mar 2026 | -$75.93M | +0.5% | — | 547.9% | |
| Peer median (excluding ZURA) | -$63.19M | +9.7% | — | 202.9% | |
Competitors are the stored peer set for ZURA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 0 | 23.69M | 44M | 24.4M | 42.08M |
| Selling, General & Admin | 1.09M | 3.47M | 18.64M | 30.79M | 33.16M |
| Operating Expenses | 1.09M | 27.16M | 62.64M | 55.19M | 75.25M |
| Depreciation & Amortization | 0 | 0 | 0 | 9K | 49K |
| EBITDA | 8.42M | (27.33M) | (60.56M) | (52.39M) | (68.6M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (1.09M) | (27.16M) | (62.64M) | (55.19M) | (75.25M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 23.48K | 570 | 2.19M | 8M | 6.34M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 9.51M | (171K) | 2.08M | 2.79M | 6.6M |
| Income Before Tax | 8.42M | (27.33M) | (60.56M) | (52.4M) | (68.65M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | 8.42M | (25.74M) | (60.36M) | (52.4M) | (68.65M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | 0.40 | 0.21 | (2.09) | (0.60) | (1.06) |
| EPS (Diluted) | 0.40 | 0.21 | (2.09) | (0.60) | (1.06) |
| Weighted Avg Shares | 17.25M | 17.25M | 33.06M | 75.07M | 94.16M |
| Weighted Avg Shares (Diluted) | 17.25M | 17.25M | 33.06M | 75.07M | 94.16M |
Zura Bio Limited
NASDAQ:ZURA
Intrinsic Alpha fair value
Locked
Current Price
$0.97
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.